drugset / Trial / NCT06006546
The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies
Phase 1
Active not recruiting
35 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
Timeline
- Start
- 2024-01-03
- Primary completion
- 2026-10-27
- Completion
- 2026-10-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 426c.Mod.Core-C4b | Protein / enzyme biologic | 100 ug | — |
| Subject | 426c.Mod.Core-C4b | Protein / enzyme biologic | 300 ug | — |